Loading clinical trials...
Loading clinical trials...
Randomized, Parallel Group, Dose Escalation Trial of Pioglitazone Versus Empagliflozin for Chronic Pancreatitis/Recurrent Acute Pancreatitis Associated Diabetes Mellitus: The PEP-DM Trial
Conditions
Interventions
Pioglitazone (PIO)
Empagliflozin (EMPA)
Locations
2
United States
Mayo Clinic
Rochester, Minnesota, United States
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States
Start Date
May 29, 2025
Primary Completion Date
May 31, 2027
Completion Date
May 31, 2027
Last Updated
April 3, 2026
NCT07224321
NCT07536516
NCT07232537
NCT07340320
NCT06513026
NCT03937453
Lead Sponsor
Mayo Clinic
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions